- Contraception For Teens: Let's Talk About It
- Gounder Gives Lowdown on Ebola, Peptides, and Colorectal Screenings
- ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
- ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
- 6 dental technology updates in May
- From clinician to leader: Building confidence, capability and leadership in dentistry
- Operationalizing AI at scale: A practical framework for enterprise-scale success
- 3 key stats on the orthodontist workforce
- Meet the COOs of 10 specialty DSOs
- Data, cross-training, and pipeline development: How health systems are rethinking OR staffing
- How top health systems are redefining the digital patient experience
- ‘The most significant change in 20 years’: Cancer centers prepare for daraxonrasib demand
- A Smooth Handoff From Decision to Dollars: Connecting the Last Mile in Healthcare Payments
- Budget-Strapped Montana Will Stress-Test Trump’s Medicaid Work Rules
- How CEOs actually use hospital rankings — and when they don’t
- What OU Health’s founding CEO learned building a new health system
- Arkansas hospital CEO to step down after 11 years for new role
- The behavioral health workforce pipeline: Where it stands and where it’s headed
- 6 major investments in youth behavioral health
- Coalition for Health AI unveils governance playbook for systems
- 66 health systems ranked by long-term debt
- UnitedHealthcare drops some prior auth requirements for cardiology, orthopedic services
- 8 No Surprises Act shake-ups physicians need to know
- The ASC independence playbook: 3 leaders’ thoughts
- Dr. Rahimah Maina opens new dental practice
- GWU offloaded its $450M physician group problem — why the industry watching
- The gastroenterologist pay gap
- Texas surgery center to double in size, add 2 ORs
- What dental leaders told us in May
- Climate Change: Statement on Proposed Rescission of Climate-Related Disclosure Rules
- Kenyan Court Blocks Trump's Plan To Quarantine Ebola Patients
- What’s going on at the FTC? 3 notes for ASC leaders
- 8 DSOs making headlines
- The physician noncompete battle in 5 key figures
- The physician red flags that can predict a bad ASC partner
- Patient death draws renewed CMS scrutiny at HCA’s Mission Hospital
- Nearly 70% of US counties lack a GI: 13 concerning workforce stats
- Statement of Commissioner Mark T. Uyeda on the Rescission of Climate-Related Disclosure Rules
- A new behavioral health profession is born
- Keynote Remarks at the 2026 Reagan National Economic Forum
- Statement on Proposing Release for Rescission of Climate-Related Disclosure Rules
- Dentists’ pay climbed the most in these 10 states
- Mental Health Disorders Now No. 1 Cause of Disability Worldwide
- Massachusetts AG sues UnitedHealthcare over alleged Medicaid fraud
- UnitedHealthcare to nix nearly two thirds of pediatric prior auths
- Industry Voices—Patients are building a new healthcare system. The industry is finally catching up
- Weekly Rundown—Moffitt Cancer Center expands Reimagine Care's virtual oncology model; Tanner Health deploys AI workforce solution
- Study: LA Canine Outbreak Caused By Low Vaccination Rates, Crowded Boarding
- Ocrelizumab Effective In Slowing Progressive MS, Trial Shows
- Long COVID Might Be Twice As Common As Previously Thought
- In Vaccine-Skeptical California County, A Potential Playbook To Contain Measles
- Heavy Drinking Harms College Students' Brain Power, Study Finds
- A Trump Stronghold Grapples With Health Risks of ICE Detention Sites
- After Her Bout of Amnesia, a $59,000 Billing Dispute Wouldn’t Go Away
- Pharma urged to modernize patient support as young adult cancer rates rise
- Philips adds a spoonful of Disney sugar to ease kids’ MRI anxieties
- MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
- Aetna to launch ‘on demand’ virtual mental health services in 2027
- U of Connecticut dental school reappoints dean for 2nd term
- Michigan dentist charged with Medicaid fraud
- Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
- ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
- Acadia in the headlines: 6 things to know
- 26 behavioral health executive moves to know
- AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
- Advocate Health grows Q1 revenue by 10.8% amid higher volumes, greater efficiency
- Behavioral health hospital operator to pay $32M in Medicare fraud settlement
- Bangladesh Measles Surge Kills 500+ Children; Vaccine Delays Blamed
- Care navigation startup Garner Health banks $100M series E at $2.74B valuation
- HCA bolsters workforce pipeline with healthcare professional college acquisition
- Plant-Based Diet May Cut Obesity Risk For Women In Menopause
- Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge
- Penn Medicine, K Health partner to deploy AI clinical agents
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CMS finalizes changes to No Surprises Act dispute resolution process
- Smartwatch App Accurately Detects Major Epileptic Seizures
- Racial Gap Exists For Asthma Inhaler Use
- New Colon Cancer Screening Guidelines Add Blood And At-Home Tests
- Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
- CVS expands partnership with Salesforce for greater call center personalization
- Nurse Convicted In Patient's Death Turns Fatal Drug Error Into Cautionary Tale
- Wearable Ultrasound Patch Monitors High-Risk Pregnancies In Real Time
- Listen to the Latest ‘KFF Health News Minute’
- In a Vaccine-Skeptical California County, a Potential Playbook To Contain Measles
- Teladoc Health inks partnership with Walmart to expand virtual care services
- PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion
- Kaléo speaks up on allergy awareness to amplify patient stories
- Privacy and PetShops: Remarks at the Regulatory PETshop Series: Cryptographic Technologies and Financial Services Regulation
- NYC Health + Hospitals adds 2nd behavioral health housing site
- Mindfulness isn’t a perk anymore — it’s a workforce strategy
- With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
- Hospitals again ask FTC, DOJ for exemption from expanded premerger notification filings
- Coalition for Health AI unveils governance playbooks for responsible AI adoption
- Amazon taps Roy Schoenberg to lead healthcare business as Neil Lindsay plans to step down
- Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
- U.S. To Keep Ebola-Exposed Citizens In Kenya Under New Policy
- CAT on a Hot Tin Roof
- GLP-1 Meds May Help Slow the Spread of Certain Obesity-Related Cancers
- GoodRx launches subscription program for low-cost generic medications, telehealth services
- George Washington University locks deal to hand off debt-ridden physician practice to UHS
- Humana invests $83M in new Florida pharmacy distribution center
- As J&J separates from its orthopedics business, it's laying off 56 employees in New Jersey
- ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
- An insider’s look at LillyDirect
- GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and China
- Weight-Loss Program Helps Women Battling Breast Cancer
- Younger U.S. Women of Color Face Rising Breast Cancer Deaths
- High Fitness Doesn’t Raise A-fib Risk In Young Men, Study Finds
- Cheaper, Alternative Health Plans Are Having A Moment, But Critics Urge Caution
- Ultrafine Wildfire Smoke Particles May Pose Serious Health Risks
- Montana Hurries To Adopt Trump’s Medicaid Work Rules Amid Budget Woes
- Readers Address Drugged Driving, Suicide Prevention, Worker Shortages
- Nurse Convicted in Patient’s Death Turns Fatal Drug Error Into a Cautionary Tale
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims
- FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
- Eli Lilly wins argument over Noom’s GLP-1 dosing claims
- Remarks at the Stanford Rock Center for Corporate Governance
- Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
- Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
- JD Power: Cost pressures worsen member experience with commercial plans
- Trump Admin Bars Key U.S. Researchers From Global Virus Response Talk
- Listen to the Latest ‘KFF Health News Minute’
- As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
- Everyone Has A Family Doc, But Can You Get An Appointment?
- Many U.S. College Students With Psychosis Are Not Receiving Treatment
- Antibiotics Won't Help Ease Asthma-Linked Wheezing in Kids
- Yoga Eases Insomnia And Anxiety In Cancer Survivors, Study Finds
- Dust Yields Clues to Viral Outbreaks, Study Finds
- 3 Medical Routines That Older People May Not Need
- Acting NIAID Chief Steps Down Amid Ebola, Hantavirus Concerns
- Sunscreen Confusion Puts More Americans At Risk For Melanoma
- 1 In 10 U.S. Surgeons Quit Practice, Study Warns Of Shortage
- Video Game Can Detect Depression In Minutes, Study Says
- Quitting Smoking Might Lower Your Dementia Risk
- Severe Asthma Often Comes With Other Serious Health Problems
- Efforts To Understand The Nation's Drugged Driving Problem Stall Under Trump
- RFK Jr. Fires Two Leaders Of Major U.S. Health Task Force
- Common Food Preservatives Linked to Major Heart Problems
- Migraine With Aura Linked To Middle-Age Stroke Risk
- Nicotine Vapes Triple Smokers' Odds Of Quitting Tobacco
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- The failure of the ‘usual suspects’ approach to life science recruitment
- The failure of the ‘usual suspects’ approach to life science recruitment
- Statement on Novel Exchange-Traded Funds (ETFs)
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
CCHFreedom reports the FDA trial no one else wants to touch in the US Court of Appeals for the Fifth Circuit in Louisiana.
From this week's newsletter.
Curious to know if these plaintifs are part of Front Line Docs.
FDA on Trial for Deadly Ivermectin Lies
FDA Claims Scientific Evidence Not Required to Make “Scientific” Claims
The FDA is rightly on trial for their deadly actions related to ivermectin. This quick 49-minute court hearing on August 8, 2023 — Apter vs. HHS, filed by Drs. Apter, Bowden, and Marik — was instructive and astonishing.
Several times, the judges had to insist that the FDA’s attorney, Ashley Cheung Honold, answer a question rather than obfuscate.
As Jared Kelson, the attorney for the three physicians (plaintiffs) said, “The fundamental issue in this case is straight forward.” He noted that nearly 40% of prescriptions prescribed in the U.S. are for off-label use and said: “After the FDA approves a human drug for sale, does it then have authority to influence or interfere with how the drug is used within the patient-doctor relationship? The answer is no.” He further stated that Congress prohibited it.
But the FDA’s attorney, who carefully referred only to ivermectin for animals as though that will exempt them from the impact their statements had on availability of ivermectin for humans, made several astonishing claims:
JUST HAVING FUN: The FDA’s “You’re not a horse…Stop it” tweet was “merely quips.”
NOT A COMMAND: “In some contexts those words could be construed as a command, but in this context where FDA was simply using these words as a quippy tweet meant to share its information article, those words do not rise to the level of a command.”
NO SCIENTIFIC PROCESS: Regularly claimed to the judges that scientific analysis of ivermectin had been performed but then admitted, “I don’t think there’s anything in the record that specifically tracked FDA’s process.”
NOT YOUR BUSINESS: “It’s not the role of the court to police the statements of an agency charged by Congress with making sure that drugs are safe or effective.” [Since ivermectin is safe and effective, why not say so?]
ROGUE: When challenged about the FDA’s authority to give its views, whether scientifically tested or not, “There’s nothing in the multiple sources of authority that I’ve cited that require FDA to go through any formal process.”
MEDICAL ADVICE: “No, your honor, the government is not conceding [that it cannot give medical advice]…It is not only permissible, but it is imperative that the FDA be able to inform the public about their scientific view about safe uses of drugs.”
WE HAD NOTHING TO DO WITH IT: When asked if FDA had obligation to speak up when hearing that hospitals and pharmacies were denying ivermectin based on FDA’s statements: “No, your honor, those hospitals and pharmacies are sophisticated independent third parties who are not controlled by the FDA.”
COURT HAVE NO ROLE: When asked who should hold FDA accountable if courts can’t: “The public can elect its government officials and FDA like other government agencies have politically accountable heads of the agency who are held accountable by the political process. It’s not the role of the courts to fact-check the FDA’s scientific statements meant to further their mission to protect the public from dangerous use of this drug.”
If the judges’ questions are any indication, the physicians will win in this case. Stay tuned. I expect this case to be appealed, whatever the decision. To hear the FDA’s attorney making these audacious claims of authority and innocence, start at the 17:30 minute mark.Good News on Ivermectin Safety
The FDA knew how safe ivermectin was. And now, a first-ever study verifies thesafety of ivermectin. An April 2023 study of ivermectin poisoning out of Cameroon found that a young woman trying to commit suicide took 400 pills of ivermectin (3 mg/each), which is about 100 times the recommended dose. Her neurological and gastric symptoms were treated at the hospital for five days and she was released. She has passed the baccalaureate test and entered the university.
Full newsletter, internal link to the trial video, and more information about CCHF here.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















